Schmitt, Walter
Diedrich, Christian
Hamza, Taye H.
Meyer, Michaela
Eissing, Thomas
Breitenstein, Stefanie
Rossano, Joseph W.
Lipshultz, Steven E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure
https://doi.org/10.1007/s00246-024-03489-7
Documents that mention this clinical trial
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure
https://doi.org/10.1007/s00246-024-03489-7
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL53392)
National Institutes of Health (HL139968)
Children's Cardiomyopathy Foundation
Kyle John Rymiszewski Foundation
Article History
Received: 30 January 2024
Accepted: 1 April 2024
First Online: 9 May 2024
Declarations
:
: JR is a consultant for Abiomed, Bayer, Cytokinetics, and Myokardia. WS, CD, MM, TE, and SB are employees of Bayer AG and may own stock in the company; TH and SL report no competing interests but SL reports being the chair of the Children’s Cardiomyopathy Foundation (CCF) medical advisory board and their Chief Medical Officer. SL is also on the medical advisory board of Secretome Therapeutics, was also a Bayer consultant, and a member of the Roche DSMB. SL has also served in the following editorial roles: American College of Cardiology (Editor), Elsevier (Editor), Biomed Central (Editor), American Heart Association (Scientific Statement Chair).